Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > NUCRYST Pharmaceuticals begins Phase 2 clinical trial

December 4th, 2003

NUCRYST Pharmaceuticals begins Phase 2 clinical trial

Abstract:
NUCRYST Pharmaceuticals Corp., a subsidiary of The Westaim Corporation, today announced that it has
begun its first Phase 2 human clinical trial of a topical cream formulation of its nanocrystalline silver. The investigational drug (NPI 32101) is being studied for atopic dermatitis, a form of eczema, and other skin conditions and represents a biological application of nanotechnology.

Source:
PRNewswire

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Tracking a Killer: UCSB, UCSD and SBP researchers trace the complex and variable pathways to the deadly condition known as sepsis October 12th, 2018

Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018 October 11th, 2018

Nano Pharmaceutical Developed to Target Cancer Cells October 10th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project